Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.

Mitsui, Shohei; Oe, Yuji; Sekimoto, Akiyo; Sato, Emiko; Hashizume, Yamato; Yamakage, Shu; Kumakura, Satoshi; Sato, Hiroshi; Ito, Sadayoshi; Takahashi, Nobuyuki

Mitsui, Shohei; Oe, Yuji; Sekimoto, Akiyo; Sato, Emiko; Hashizume, Yamato; Yamakage, Shu; Kumakura, Satoshi; Sato, Hiroshi; Ito, Sadayoshi; Takahashi, Nobuyuki.

Afiliação

Mitsui S; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Oe Y; Department of Community Medical Support, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Sekimoto A; Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Sato E; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Hashizume Y; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Yamakage S; Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kumakura S; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Sato H; Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ito S; Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takahashi N; Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.

Am J Physiol Renal Physiol ; 318(5): F1067-F1073, 2020 05 01.

Article em En | MEDLINE | ID: mdl-32200667

Assuntos

Diabetes Mellitus Tipo 1/tratamento farmacológico; Nefropatias Diabéticas/prevenção & controle; Iminas/farmacologia; Rim/efeitos dos fármacos; Oligopeptídeos/farmacologia; Piridinas/farmacologia; Receptor PAR-1/antagonistas & inibidores; Receptor PAR-2/antagonistas & inibidores; Albuminúria/genética; Albuminúria/metabolismo; Albuminúria/prevenção & controle; Animais; Linhagem Celular; Proliferação de Células/efeitos dos fármacos; Colágeno Tipo IV/metabolismo; Citocinas/metabolismo; Diabetes Mellitus Tipo 1/genética; Diabetes Mellitus Tipo 1/metabolismo; Nefropatias Diabéticas/genética; Nefropatias Diabéticas/metabolismo; Nefropatias Diabéticas/patologia; Modelos Animais de Doenças; Quimioterapia Combinada; Células Endoteliais/efeitos dos fármacos; Células Endoteliais/metabolismo; Fibrose; Humanos; Mediadores da Inflamação/metabolismo; Rim/metabolismo; Rim/patologia; Camundongos da Linhagem 129; Camundongos Endogâmicos C57BL; Camundongos Knockout; Óxido Nítrico Sintase Tipo III/deficiência; Óxido Nítrico Sintase Tipo III/genética; Receptor PAR-1/metabolismo; Receptor PAR-2/metabolismo; Transdução de Sinais

Palavras-chave

coagulation; cytokine; endothelium; fibrosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Piridinas / Receptor PAR-1 / Receptor PAR-2 / Diabetes Mellitus Tipo 1 / Nefropatias Diabéticas / Iminas / Rim Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google